<--GAT-->
Clinical Topics

Erectile Dysfunction Drugs and Skin Cancer in Veterans

by U.S. Medicine

May 23, 2019

LEXINGTON, KY—Is there a relationship between phosphodiesterase 5 inhibitor drugs, prescribed for erectile dysfunction, and skin cancers? A large-scale study of veterans sought to determine that.

A retrospective review using the VAs Informatics and Computing Infrastructure database was recently published in the journal Urology.1

For the study, Lexington, KY, VAMC and University of Kentucky-led researchers searched the database over 19 years to identify veterans who received PDE5i treatment for erectile dysfunction. Veterans who never took the drugs were used for comparison analysis. In both groups, follow-up time, outpatient clinic visits and incidence of malignant melanoma and basal cell carcinoma were measured.

Included were 2.55 million veterans were included in this study, 1.27 million in each group. Mean age of the PDE5i group and non-PDE5i group was 59.2 years (standard deviation [SD] ± 10.8) and 58.7 (SD ± 10.8), respectively. Mean follow-up time for the PDE5i group was 8.9 years (SD ± 4.2) and 8.5 years (SD ± 4.3) for non-PDE5i group.

Results indicated that the odds ratio for malignant melanoma and BCC in the PDE5i group was 1.25 (confidence interval 95%, 1.22-1.28, P <.0001) and 1.49 (confidence interval 95%, 1.46-1.51, P <.0001), respectively. PDE5i users also showed more mean outpatient visits/year (8.9 SD ± 9.50) compared to non-PDE5i users (5.9 SD ± 10.0; P <.0001), the study team noted.

“Veterans prescribed PDE5is to treat erectile dysfunction show a minimal increased risk of MM and a greater risk of BCC compared to non-PDE5i users,” study authors concluded. “PDE5i users visited outpatient VA clinics at a higher rate than non-PDE5i users in this study. These findings suggest confounding variables are likely involved in the relationship between skin cancers and PDE5i use. PDE5i drugs remain a safe treatment for erectile dysfunction.”

1 Christie A, Vera PL, Higgins M, Kumar S, Lane M, Preston D. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans. Urology. 2019 Apr;126:116-120. doi: 10.1016/j.urology.2019.01.025. Epub 2019 Feb 5. PubMed PMID: 30735744.



Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging... View Article

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and... View Article


U.S. Medicine Recommends


More From dermatology

Dermatology

IBD Treatment Can Increase Squamous Cell Cancer Risk

CDC, VA Authors Reject Calls to Lessen Interventions SALT LAKE CITY—Concerned about methicillin-resistant Staphylococcus aureus, one of the most common causes of healthcare-associated infections, the VA piloted a MRSA prevention program in 18 VAMCs beginning... View Article

Dermatology

High Satisfaction with Teledermatology at Atlanta VAMC

CDC, VA Authors Reject Calls to Lessen Interventions SALT LAKE CITY—Concerned about methicillin-resistant Staphylococcus aureus, one of the most common causes of healthcare-associated infections, the VA piloted a MRSA prevention program in 18 VAMCs beginning... View Article

Dermatology

Living With a Mystery Disease: One Woman’s Story

At 31, Susan Thornton developed an itchy rash around her waist.

Dermatology

Soft Tissue Infections in Military Trainees

Military trainees are at high risk for skin and soft-tissue infections (SSTIs) but, while Staphylococcus aureus is associated with purulent SSTI, it is unclear to what degree this pathogen causes nonpurulent cellulitis.

Dermatology

Types of Skin Lesions Referred by PCPs at VA

MINNEAPOLIS—Skin lesions sent to dermatology by primary care physicians (PCPs) represent a significant proportion of VA healthcare visits, according to a new study.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up